A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) (NCT05582993)
A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With Vonicog Alfa (rVWF) in Children Diagnosed With Severe Von Willebrand Disease
🩺 Plain-English Summary (8th-Grade Level)
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor \[rVWF\]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months. During the study, participants will visit the study clinic 5 times after treatment initiation.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: Not specified to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Bleeding and Clotting Disorders Institute — Peoria, Illinois
- Riley Hospital for Children Indiana University Health — Indianapolis, Indiana
- University of Iowa Hospitals & Clinics PARENT — Iowa City, Iowa
- Childrens Hospital of Michigan — Detroit, Michigan
- Michigan State University Center for Bleeding Disorders & Clotting Disorders — East Lansing, Michigan
- Children's Health Care d/b/a Children's Minnesota — Minneapolis, Minnesota
- Cure 4 the Kids — Las Vegas, Nevada
- Rutgers - Robert Wood Johnson Medical School — New Brunswick, New Jersey
- New York - Presbyterian/Weill Cornell Medical Center — New York, New York
- Medical University of South Carolina (MUSC) — Charleston, South Carolina
- Hemostase Clinique - Institut Cœur-Poumons (4eme étage aile est) Bureau 419 — Lille,
- Hopital Edouard Herriot - CHU Lyon — Lyon,
- Children's Health Ireland — Dublin,
- Azienda Ospedaliera Pediatrica Santobono Pausillipon — Naples,
- Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino — Turin (Torino),
- Japanese Red Cross Narita Hospital — Narita, Chiba
- Nara Medical University Hospital — Kashihara, Nara
- NHO Beppu Medical Center — Beppu, Oita Prefecture
- Nagasaki University Hospital — Nagasaki,
- Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust — London,
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Von Willebrand Disease (VWD)
- A Study of Bleeding and Treatment in Participants With Von Willebrand Disease — Phoenix, Arizona
- A Study Assessing HMB-002 in Participants With Von Willebrand Disease — Phoenix, Arizona
- Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) — Little Rock, Arkansas
- HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — Los Angeles, California
Explore by condition: All Von Willebrand Disease (VWD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.